Beijing, May 25th, 2022 — The R&D-based Pharmaceutical Association Committee (RDPAC) has announced a change in membership of the RDPAC Executive Committee 2022-2023. Rogier Janssens, the outgoing Managing Director and General Manager of Merck China Healthcare, has been appointed to a new position within Merck, and as a result, will leave his position as Vice-chairman of the RDPAC Executive Committee 2022-2023. Based on the election results for the RDPAC Executive Committee for 2022-2023, Julio Gay-Ger, Lilly China President and General Manager, has assumed the role of Vice-chairman of the RDPAC Executive Committee 2022-2023, and Vivian Bian, CEO of Roche Pharma China, has been co-opted as a member of the RDPAC Executive Committee 2022-2023. The changes became effective on May 1, 2022.
“I would like to express my sincere appreciation of the trust RDPAC and member companies have given me. I am very honored to be elected Vice-Chairman of the Executive Committee. In my tenure, I would like to work closely with other EC members and member companies to contribute to the healthy and sustainable development of China’s biopharmaceutical industry, benefit more Chinese patients with innovative medicines, and aid the realization of the ‘Healthy China’ Initiative. Meanwhile I will continue to carry out my duties in Ethical Business Practice, advocate for IPR Protection and help build a healthy industry ecosystem”, said Julio Gay-Ger, newly appointed Vice-chairman of the RDPAC Executive Committee 2022-2023.
Vivian Bian, member of RDPAC Executive Committee 2022-2023, said: “It is a great honor for me to join the RDPAC Executive Committee and contribute my best effort as a member. As an important bridge and link that connects the government, pharma companies and the healthcare industry, RDPAC has always been striving to advance a series of initiatives to foster the healthcare innovation ecosystem in China. In the future, I look forward to working with you all to explore innovative models, build a patient-centric healthcare ecosystem, and contribute to China’s ambition to become a global innovation powerhouse as well as the Healthy China 2030 Initiative.”
During his five-year tenure with the RDPAC Executive Committee, Rogier Janssens showed great leadership both in his role as the Vice-chairman, and in having led RDPAC’s Communication Committee. In the latter role he launched RDPAC’s high-profile International Pharmaceutical Innovation Conference (IPIF) initiative, designed as a platform for dialogue between government and industry, and which has gained wide recognition among government agencies, industry, universities and research institutions, with successful conferences having been held in 2019 and 2021. Sincere thanks go to Rogier for the commitment and effort he showed during his tenure at RDPAC, advocating for the pharmaceutical industry and in so doing helping to build a flourishing healthcare industry in China. We wish him all the best in his future endeavors.
The new RDPAC Executive Committee leadership team will continue to spearhead the Committee’s work in accordance with its five strategic pillars, namely: accelerate innovation, access innovation, protect innovation, advocate innovation and compliance and ethics, and to strive towards achieving the goal of “Healthy China 2030”.